Wilms' tumor 1 (WTl) peptide immunotherapy for gynecological malignancy

Anticancer Research

Volumn 29, Issue 11, 2009, Pages 4779-4784

  Ohno, Satoshi ^a,b   Kyo, Satoru ^b   Myojo, Subaru ^b   Dohi, Satoshi ^b   Ishizaki, Junko ^b   Miyamoto, Ken Ichi ^c   Morita, Satoshi ^d   Sakamoto, Jun Ichi ^e   Enomoto, Takayuki ^f   Kimura, Tadashi ^f   Oka, Yoshihiro ^f   Tsuboi, Akihiro ^f   Sugiyama, Haruo ^f   Inoue, Masaki ^b  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^d YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^e NAGOYA UNIVERSITY   (Japan)

^f OSAKA UNIVERSITY   (Japan)

Author keywords

Cancer vaccine; Immunotherapy; Peptide; Wilms' tumor 1; WTl

Indexed keywords

ANTINEOPLASTIC AGENT; HLA A ANTIGEN; MONTANIDE ISA 51; UNCLASSIFIED DRUG; WILMS TUMOR PEPTIDE;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CANCER CONTROL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DELAYED HYPERSENSITIVITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; INJECTION SITE ERYTHEMA; INJECTION SITE INFLAMMATION; OVARY CANCER; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR VOLUME; URINALYSIS; UTERINE CERVIX CANCER; UTERUS CARCINOMA; UTERUS SARCOMA; VACCINATION;

ADULT; AGED; CANCER VACCINES; FEMALE; GENITAL NEOPLASMS, FEMALE; HLA-A ANTIGENS; HUMANS; INJECTIONS, INTRADERMAL; MIDDLE AGED; PEPTIDE FRAGMENTS; WT1 PROTEINS;

EID: 75149119734     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Oka Y, Tsuboi A, Elisseeva OA, Udaka K and Sugiyama H: WTl as a novel target antigen for cancer immunotherapy. Curr Cancer Drag Targets 2: 45-54, 2002.
2. Oka Y, Tsuboi A, Oji Y, Kawase I and Sugiyama H: WTl peptide vaccine for the treatment of cancer. Curr Opin Immunol 20:211-220,2008.
3. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, Rose EA, Kral A, Yeger H, Lewis WH, Jones C and Housman DE: Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60: 509-520, 1990.
4. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH and Bruns GA: Homozygous deletion in Wilms' tumours of a zinc-finger gene identified by chromosome jumping. Nature 343: 774-778, 1990.
5. Sugiyama H: Wilms' tumor gene WTl: its oncogenic function and clinical application. Int J Hematol 73: 177-187, 2001.
6. Oka Y, Tsuboi A, Kawakami M, Elisseeva OA, Nakajima H, Udaka K, Kawase I, Oji Y and Sugiyama H: Development of WTl peptide cancer vaccine against hematopoietic malignancies and solid cancers. Curr Med Chem 13: 2345-2352, 2006.
7. Yang L, Han Y, Suarez Saiz F and Minden MD: A tumor suppressor and oncogene: the WTl story. Leukemia 21: 868-876,2007.
8. Nakatsuka S, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T, Kawano K, Kuwae Y, Yamauchi A, Okumura M, Kitamura Y, Oka Y, Kawase I, Sugiyama H and Aozasa K: Immunohistochemical detection of WTl protein in a variety of cancer cells. Mod Pathol 19:804-814,2006.
9. Ohno S, Dohi S, Ohno Y, Kyo S, Sugiyama H, Suzuki N and Inoue M: Immunohistochemical detection of WTl protein in endometrial cancer. Anticancer Res 29: 1691-1696, 2009.
10. Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, Elisseeva OA, Oji Y, Kawakami M, Ikegame K, Hosen N, Yoshihara S, Wu F, Fujiki F, Murakami M, Masuda T, Nishida S, Shirakata T, Nakatsuka S, Sasaki A, Udaka K, Dohy H, Aozasa K, Noguchi S, Kawase I and Sugiyama H: Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 101: 13885-13890, 2004.
11. Morita S, Oka Y, Tsuboi A, Kawakami M, Maruno M, Izumoto S, Osaki T, Taguchi T, Ueda T, Myoui A, Nishida S, Shirakata T, Ohno S, Oji Y, Aozasa K, Hatazawa J, Udaka K, Yoshikawa H, Yoshimine T, Noguchi S, Kawase I, Nakatsuka S, Sugiyama H and Sakamoto J: A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. Jpn J Clin Oncol 36: 231-236,2006.
12. Iiyama T, Udaka K, Takeda S, Takeuchi T, Adachi YC, Ohtsuki Y, Tsuboi A, Nakatsuka S, Elisseeva OA, Oji Y, Kawakami M, Nakajima H, Nishida S, Shirakata T, Oka Y, Shuin T and Sugiyama H: WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma. Microbiol Immunol 51: 519-530, 2007.
13. Tsuboi A, Oka Y, Nakajima H, Fukuda Y, Elisseeva OA, Yoshihara S, Hosen N, Ogata A, Kito K, Fujiki F, Nishida S, Shirakata T, Ohno S, Yasukawa M, Oji Y, Kawakami M, Morita S, Sakamoto J, Udaka K, Kawase I and Sugiyama H: Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. Int J Hematol 86: 414-417, 2007.
14. Izumoto S, Tsuboi A, Oka Y, Suzuki T, Hashiba T, Kagawa N, Hashimoto N, Maruno M, Elisseeva OA, Shirakata T, Kawakami M, Oji Y, Nishida S, Ohno S, Kawase I, Hatazawa J, Nakatsuka S, Aozasa K, Morita S, Sakamoto J, Sugiyama H and Yoshimine T: Phase II clinical trial of Wilms' tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 108:963-971,2008.
15. Tsuboi A, Oka Y, Udaka K, Murakami M, Masuda T, Nakano A, Nakajima H, Yasukawa M, Hiraki A, Oji Y, Kawakami M, Hosen N, Fujioka T, Wu F, Taniguchi Y, Nishida S, Asada M, Ogawa H, Kawase I and Sugiyama H: Enhanced induction of human WTl-specific cytotoxic T lymphocytes with a 9-mer WTl peptide modified at HLA-A*2402-binding residues. Cancer Immunol Immunother 51: 614-620, 2002.
16. http://ctep.cancer.gov/protocolDevelopment/electronic- applications/docs/ctcaev3 .pdf
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
18. Tsuboi A, Oka Y, Ogawa H, Elisseeva OA, Li H, Kawasaki K, Aozasa K, Kishimoto T, Udaka K and Sugiyama H: Cytotoxic Tlymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination. J Clin Immunol 20: 195-202,2000.
19. Oka Y, Tsuboi A, Oji Y, Kawase I and Sugiyama H: WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol 20:211-220,2008.
20. Curiel TJ: Regulatory T-cells and treatment of cancer. Curr Opin Immunol 20: 241-246, 2008.
21. Nakajima H, Kawasaki K, Oka Y, Tsuboi A, Kawakami M, Ikegame K, Hoshida Y, Fujiki F, Nakano A, Masuda T, Wu F, Taniguchi Y, Yoshihara S, Elisseeva OA, Oji Y, Ogawa H, Azuma I, Kawase I, Aozasa K and Sugiyama H: WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone. Cancer Immunol Immunother 53: 617-624, 2004.
22. + patients with metastatic breast and ovarian cancer. Clin Cancer Res 8: 3407-3418, 2002.
23. Slingluff CL Jr, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Hibbitts S, Teates D, Neese PY, Grosh WW, Chianese-Bullock KA, Woodson EM, Wiernasz CJ, Merrill P, Gibson J, Ross M and Engelhard VH: Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 21: 4016-4026, 2003.
24. + T-cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 115: 739-746,2005.
25. Di Pucchio T, PiIIa L, Capone I, Ferrantini M, Montefiore E, Urbani F, Patuzzo R, Pennacchioli E, Santinami M, Cova A, Sovena G, Arienti F, Lombardo C, Lombardi A, Caporaso P, D'Atri S, Marchetti P, Bonmassar E, Parmiani G, Belardelli F and Rivoltini L: Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T-cells and monocyte/dendritic cell precursors. Cancer Res 66: 4943-4951, 2006.
26. Rosenberg SA, Yang JC, Schwartzentraber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH and White DE: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4: 321-327,1998.